HIV vaccine nanoparticle and mRNA booster for healthy adults
Part of Infections clinical trials.
This study tests a new HIV vaccine that uses tiny particles (nanoparticles) and an mRNA booster — similar to some COVID vaccines. The goal is to see if it is safe and helps your body fight HIV. It's for healthy adults who do not have HIV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 55 years old.
- You must be in good general health, with no major medical conditions.
- You must not be living with HIV, and you must test negative for HIV at the start.
- You must be willing to practice effective birth control (if applicable) during the study.
- You must not have received an experimental HIV vaccine before.
- You must not have had myocarditis (heart muscle inflammation) or pericarditis (inflammation around the heart) in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new two-part HIV vaccine regimen in healthy adults without HIV. The goal is to see if it is safe and produces an immune response that could help prevent HIV.
This study tests two experimental mRNA-based HIV vaccines to see if they are safe and create an immune response. It is for healthy adults aged 18 to 55 who do not have HIV.
This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.
This trial tests an experimental HIV vaccine in healthy adults, including those living with HIV. The goal is to see if the vaccine is safe and prompts an immune response.
This trial tests a combination of an HIV vaccine and a new antibody treatment (GS-2872) to see if it can help control HIV without daily pills. It is for people with well-controlled HIV who are looking for ways to reduce their dependence on antiretroviral therapy.
This study is testing three experimental antibodies (ePGT121v1-LS, PGDM1400LS, and VRC07-523LS) that may help prevent HIV. It’s looking at their safety and how long they stay in the body. Healthy volunteers without HIV can join.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.